Startup profile · funding coverage
AnaCardio funding, valuation and investors
Swedish cardiovascular biotech that raised €62.5 million in Series B financing for a chronic advanced heart-failure program.
Keep track of AnaCardio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
€62.5M (~$70.9M) · September 29, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Stockholm, Sweden
Overview
AnaCardio is a Stockholm-based biotech developing therapies for chronic advanced heart failure. On September 29, 2026 multiple contemporaneous funding sources reported a €62.5 million (about $70.9 million) Series B intended to advance the company's heart-failure program toward registrational development. Primary release details were not available in the retrieved sources, so VCT keeps this record behind a draft review gate.
Why AnaCardio is interesting
Large European life-sciences round supporting a program moving toward registrational development.
Key facts
- Sep 29, 2026: €62.5M Series B reported
- Secondary-source verification; retain draft review
Funding history (newest first)
Series B
2026-09-29 €62.5M (~$70.9M)Source: https://biobriefs.com/fda-backs-anacardios-heart-failure
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.